Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution)

DRUG2 trials

Sponsors

Mankind Pharma Limited, Amneal Pharmaceuticals, LLC

Conditions

Glaucoma, Open-AngleOcular Hypertension

Phase 3

Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% to LUMIGAN® In The Treatment of Chronic Open-Angle Glaucoma

CompletedNCT04890106

Mankind Pharma LimitedGlaucoma, Open-Angle

Start: 2021-10-02End: 2022-08-11Updated: 2022-12-13

Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.

RecruitingNCT05401357

Amneal Pharmaceuticals, LLCGlaucoma, Open-Angle, Ocular Hypertension

Start: 2022-06-29End: 2022-12-31Target: 168Updated: 2022-08-10